KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Consolidated Net Income (2017 - 2025)

Twist Bioscience (TWST) has disclosed Consolidated Net Income for 9 consecutive years, with -$30.5 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income rose 3.44% to -$30.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$76.6 million through Dec 2025, up 61.16% year-over-year, with the annual reading at -$77.7 million for FY2025, 62.8% up from the prior year.
  • Consolidated Net Income for Q4 2025 was -$30.5 million at Twist Bioscience, down from -$27.1 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $20.4 million in Q2 2025, with the low at -$85.6 million in Q2 2024.
  • Average Consolidated Net Income over 5 years is -$42.9 million, with a median of -$42.4 million recorded in 2022.
  • The sharpest move saw Consolidated Net Income crashed 69.59% in 2021, then surged 123.83% in 2025.
  • Over 5 years, Consolidated Net Income stood at -$45.6 million in 2021, then rose by 8.21% to -$41.8 million in 2022, then decreased by 2.83% to -$43.0 million in 2023, then increased by 26.54% to -$31.6 million in 2024, then increased by 3.44% to -$30.5 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$30.5 million, -$27.1 million, and $20.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.